Top

Published in:

01-05-2010 | Original Communication

Amyloid PET in mild cognitive impairment and Alzheimer’s disease with BF-227: comparison to FDG–PET

Authors: Katsutoshi Furukawa, Nobuyuki Okamura, Manabu Tashiro, Masaaki Waragai, Shozo Furumoto, Ren Iwata, Kazuhiko Yanai, Yukitsuka Kudo, Hiroyuki Arai

Published in: Journal of Neurology | Issue 5/2010

Abstract

We recently developed a novel PET tracer, ¹¹C-labeled 2-(2-[2-dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole ([¹¹C]BF-227), and had success with in vivo detection of amyloid plaques in Alzheimer’s disease (AD) brains (Kudo et al. in J Nucl Med 8:553–561, 2007). We applied this tracer to subjects with mild cognitive impairment (MCI) and AD in order to elucidate the status of amyloid plaque deposition in MCI and compared the diagnostic performance of BF-227-PET with that of FDG–PET in AD cases. We studied 12 aged normal (AN) subjects, 15 MCIs and 15 ADs with PET using [¹¹C]BF-227. PET images were obtained after administration of BF-227 and the regional standardized uptake value (SUV) and the ratio of regional to cerebellar SUV were calculated as an index of BF-227 binding. AD patients showed increased uptake of [¹¹C]BF-227 in the neocortical areas and striatum as well as decreased glucose metabolism in temporoparietal, posterior cingulate and medial temporal areas. MCI subjects showed a significant increase in BF-227 uptake in the neocortical areas similar to AD, and the most significant difference of BF-227 retention was observed in the parietal lobe if its retentions for MCI were compared to those for AD and AN. On the other hand, glucose hypometabolism in MCI was confined to cingulate and medial temporal cortices. Neocortical BF-227 uptake negatively correlated with glucose metabolism. Receiver operating characteristic (ROC) analysis indicated higher specificity and sensitivity with BF-227-PET than those with FDG–PET for differential diagnosis between AD and normal control. We conclude that [¹¹C]BF-227-PET has a possibility to be a useful technology for early detection of AD pathology and also even in the MCI stage.

Bennett DA, Cochran EJ, Saper CB, Leverenz JB, Gilley DW, Wilson RS (1993) Pathological changes in frontal cortex from biopsy to autopsy in Alzheimer’s disease. Neurobiol Aging 14:589–596CrossRefPubMed

Chételat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron JC (2003) Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer’s disease? Neurology 60:1374–1377PubMed

Chételat G, Eustache F, Viader F, De La Sayette V, Pélerin A, Mézenge F, Hannequin D, Dupuy B, Baron JC, Desgranges B (2005) FDG–PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment. Neurocase 11:14–25CrossRefPubMed

de Leon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, Rusinek H, Tsui W, Kandil E, Scherer AJ, Roche A, Imossi A, Thorn E, Bobinski M, Caraos C, Lesbre P, Schlyer D, Poirier J, Reisberg B (2001) Fowler et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET). Proc Natl Acad Sci USA 98:10966–10971CrossRefPubMed

Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, Schwaiger M, Kurz A (2003) Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer’s disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 30:1104–1113CrossRefPubMed

Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, Ringheim A, Långström B, Nordberg A (2008) A PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 29:1456–1465CrossRefPubMed

Gómez-Isla T, Price JL, McKeel DW Jr, Morris JC, Growdon JH, Hyman BT (1996) Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer’s disease. J Neurosci 16:4491–4500PubMed

Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297:353–356CrossRefPubMed

Herholz K, Carter SF, Jones M (2007) PET studies in dementia. Br J Radiol 80:S160–S167CrossRefPubMed

10.

Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y (1994) Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13:45–53CrossRefPubMed

11.

Jicha GA, Parisi JE, Dickson DW, Johnson K, Cha R, Ivnik RJ, Tangalos EG, Boeve BF, Knopman DS, Braak H, Petersen RC (2006) Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol 63:674–681CrossRefPubMed

12.

Kemppainen NM, Aalto S, Wilson IA, Någren K, Helin S, Brück A, Oikonen V, Kailajärvi M, Scheinin M, Viitanen M, Parkkola R, Rinne JO (2007) PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 68:1603–1606CrossRefPubMed

13.

Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergström M, Savitcheva I, Huang GF, Estrada S, Ausén B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Långström B (2004) Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 55:306–319CrossRefPubMed

14.

Kudo Y, Okamura N, Furumoto S, Tashiro M, Furukawa K, Maruyama M, Itoh M, Iwata R, Yanai K, Arai H (2007) 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl) -6-(2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer’s disease patients. J Nucl Med 8:553–561

15.

Mathis CA, Klunk WE, Price JC, DeKosky ST (2005) Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies. Arch Neurol 62:196–200CrossRefPubMed

16.

Matsuda H (2007) Role of neuroimaging in Alzheimer’s disease, with emphasis on brain perfusion SPECT. J Nucl Med 48:1289–1300CrossRefPubMed

17.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34:939–944PubMed

18.

Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE (1997) Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol 42:85–94CrossRefPubMed

19.

Okamura N, Arai H, Higuchi M, Tashiro M, Matsui T, Hu XS, Takeda A, Itoh M, Sasaki H (2001) [18F]FDG–PET study in dementia with Lewy bodies and Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry 25:447–456CrossRefPubMed

20.

Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56:303–308CrossRefPubMed

21.

Petersen RC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256:183–194CrossRefPubMed

22.

Petersen RC, Parisi JE, Dickson DW, Johnson K, Cha R, Ivnik RJ, Tangalos EG, Boeve BF, Knopman DS, Braak H, Petersen RC (2006) Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol 63:665–672CrossRefPubMed

23.

Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann Neurol 45:358–368CrossRefPubMed

24.

Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, Lavretsky H, Burggren AC, Cole GM, Vinters HV, Thompson PM, Huang SC, Satyamurthy N, Phelps ME, Barrio JR (2006) PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 355:2652–2663CrossRefPubMed

Title: Amyloid PET in mild cognitive impairment and Alzheimer’s disease with BF-227: comparison to FDG–PET
Authors: Katsutoshi Furukawa
Nobuyuki Okamura
Manabu Tashiro
Masaaki Waragai
Shozo Furumoto
Ren Iwata
Kazuhiko Yanai
Yukitsuka Kudo
Hiroyuki Arai
Publication date: 01-05-2010
Publisher: Springer-Verlag
Published in: Journal of Neurology / Issue 5/2010
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-009-5396-8

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Amyloid PET in mild cognitive impairment and Alzheimer’s disease with BF-227: comparison to FDG–PET

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2010

Epstein-Barr virus, 9.4 T MRI and phosphodiesterase inhibitors in multiple sclerosis

Frequency of ubiquitin and FUS-positive, TDP-43-negative frontotemporal lobar degeneration

Insensitivity of visual assessment of hippocampal atrophy in familial Alzheimer’s disease

A bilateral foot drop due to neuroschistosomiasis

Primary central nervous system vasculitis and moyamoya disease: similarities and differences

Epilepsy during the Middle Ages, the Renaissance and the Enlightenment